Literature DB >> 33106132

A Comprehensive Overview of Colon Cancer- A Grim Reaper of the 21st Century.

Rajesh Kumar1, Seetha Harilal1, Simone Carradori2, Bijo Mathew3.   

Abstract

A few decades ago, the incidence of colorectal cancer (CRC) was low and is now the fourth in the list of deadly cancers producing nearly a million deaths annually. A population that is aging along with risk factors such as smoking, obesity, sedentary lifestyle with little or no physical activity, and non-healthy food habits of developed countries can increase the risk of colorectal cancer. The balance in gut microbiota and the metabolites produced during bacterial fermentation within the host plays a significant role in regulating intestinal diseases as well as colorectal cancer development. Recent progress in the understanding of illness resulted in multiple treatment options such as surgery, radiation, and chemotherapy, including targeted therapy and multitherapies. The treatment plan for CRC depends on the location, stage and grade of cancer as well as genomic biomarker tests. Despite all the advancements made in the genetic and molecular aspects of the disease, the knowledge seems inadequate as the drug action as well as the wide variation in drug response did not appear strongly correlated with the individual molecular and genetic characteristics, which suggests the requirement of comprehensive molecular understanding of this complex heterogeneous disease. Furthermore, multitherapies or a broad spectrum approach, which is an amalgamation of the various promising as well as effective therapeutic strategies that can tackle heterogeneity and act on several targets of the disease, need to be validated in clinical studies. The latest treatment options have significantly increased the survival of up to three years in the case of advanced disease. The fact that colorectal cancer is developed from a polypoid precursor, as well as the symptoms of the disease that occur at an advanced stage, underlines how screening programs can help early detection and decrease mortality as well as morbidity from CRC. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Colorectal cancer; microbiota; morbidity fromzzm321990CRC; multitherapies; natural compounds; targeted therapy

Year:  2021        PMID: 33106132     DOI: 10.2174/0929867327666201026143757

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  5 in total

1.  Synthesis, Cytotoxicity and Anti-Proliferative Activity Against AGS Cells of New 3(2H)-Pyridazinone Derivatives Endowed with a Piperazinyl Linker.

Authors:  Mehmet Abdullah Alagöz; Zeynep Özdemir; Mehtap Uysal; Simone Carradori; Marialucia Gallorini; Alessia Ricci; Susi Zara; Bijo Mathew
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-25

2.  Bioinformatic Analyses and Experimental Verification Reveal that High FSTL3 Expression Promotes EMT via Fibronectin-1/α5β1 Interaction in Colorectal Cancer.

Authors:  Yuanjie Liu; Jiepin Li; Shuhong Zeng; Ying Zhang; Yonghua Zhang; Zhichao Jin; Shenlin Liu; Xi Zou
Journal:  Front Mol Biosci       Date:  2021-11-24

Review 3.  Microbiota, Bacterial Carbonic Anhydrases, and Modulators of Their Activity: Links to Human Diseases?

Authors:  Amedeo Amedei; Clemente Capasso; Giulia Nannini; Claudiu T Supuran
Journal:  Mediators Inflamm       Date:  2021-11-11       Impact factor: 4.711

4.  Bioinformatic Analysis of the Effect of Silver Nanoparticles on Colorectal Cancer Cell Line.

Authors:  Fernando Martínez-Esquivias; Melva Gutiérrez-Angulo; Julieta Saraí Becerra-Ruiz; Luz Andrea Martinez-Perez; Claudia Jackelin de la Cruz-Ahumada; Juan Manuel Guzmán-Flores
Journal:  Biomed Res Int       Date:  2022-04-11       Impact factor: 3.246

Review 5.  The seen and the unseen: Molecular classification and image based-analysis of gastrointestinal cancers.

Authors:  Corina-Elena Minciuna; Mihai Tanase; Teodora Ecaterina Manuc; Stefan Tudor; Vlad Herlea; Mihnea P Dragomir; George A Calin; Catalin Vasilescu
Journal:  Comput Struct Biotechnol J       Date:  2022-09-12       Impact factor: 6.155

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.